H. Lundbeck AS (LUN):企業の財務・戦略的SWOT分析

◆英語タイトル:H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH29835FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

H. Lundbeck AS (LUN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system (CNS) diseases including psychiatric and neurological disorders. The company’s products are indicated for the treatment of diseases such as Alzheimer’s disease, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington’s disease, among others. It operates production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies and hospitals in Europe, the US and other countries. Lundbeck is headquartered in Valby, Denmark.

H. Lundbeck AS Key Recent Developments

Mar 17,2021: Lundbeck appoints Dr. Tarek Samad as Head of Research
Mar 12,2021: Lundbeck – New member proposed for election to Board of Directors
Jan 29,2021: Lundbeck and Better Energy ensures the construction of a new solar park
Jan 12,2021: Rigshospitalet and Lundbeck announce partnership to find new ways to treat brain diseases
Nov 03,2020: H. Lundbeck: Solid performance across strategic brands with 19% growth in the first nine months of 2020; financial guidance range for 2020 narrowed

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
H. Lundbeck AS – Key Facts
H. Lundbeck AS – Key Employees
H. Lundbeck AS – Key Employee Biographies
H. Lundbeck AS – Major Products and Services
H. Lundbeck AS – History
H. Lundbeck AS – Company Statement
H. Lundbeck AS – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
H. Lundbeck AS – Business Description
Product Category: Abilify Maintena
Overview
Performance
Product Category: Brintellix/Trintellix
Overview
Performance
Product Category: Cipralex/Lexapro
Overview
Performance
Product Category: Effects from Hedging
Performance
Product Category: Northera
Overview
Performance
Product Category: Onfi
Overview
Performance
Product Category: Other pharmaceuticals
Performance
Product Category: Other Revenue
Performance
Product Category: Rexulti
Overview
Performance
Product Category: Sabril
Overview
Performance
Product Category: Vyepti
Overview
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: International Markets
Target Markets
Performance
Geographical Segment: North America
Performance
R&D Overview
H. Lundbeck AS – Corporate Strategy
H. Lundbeck AS – SWOT Analysis
SWOT Analysis – Overview
H. Lundbeck AS – Strengths
H. Lundbeck AS – Weaknesses
H. Lundbeck AS – Opportunities
H. Lundbeck AS – Threats
H. Lundbeck AS – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
H. Lundbeck AS, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 17, 2021: Lundbeck appoints Dr. Tarek Samad as Head of Research
Mar 12, 2021: Lundbeck – New member proposed for election to Board of Directors
Jan 29, 2021: Lundbeck and Better Energy ensures the construction of a new solar park
Jan 12, 2021: Rigshospitalet and Lundbeck announce partnership to find new ways to treat brain diseases
Nov 03, 2020: H. Lundbeck: Solid performance across strategic brands with 19% growth in the first nine months of 2020; financial guidance range for 2020 narrowed
Aug 13, 2020: H. Lundbeck: Strong momentum across all strategic brands with 25% growth in the first half of 2020
Jun 09, 2020: Lundbeck plans to refocus and reinvigorate Research & Development
May 12, 2020: H. Lundbeck: Strong momentum across all strategic brands with 35% growth in Q1 2020, financial guidance maintained
Mar 04, 2020: Lundbeck receives grant from The Michael J. Fox Foundation for Parkinson’s disease research
Feb 06, 2020: Strong momentum with 28% growth across all strategic brands in 2019. For 2020, Lundbeck expects revenue growth of 2-6%
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
H. Lundbeck AS, Key Facts
H. Lundbeck AS, Key Employees
H. Lundbeck AS, Key Employee Biographies
H. Lundbeck AS, Major Products and Services
H. Lundbeck AS, History
H. Lundbeck AS, Subsidiaries
H. Lundbeck AS, Key Competitors
H. Lundbeck AS, Ratios based on current share price
H. Lundbeck AS, Annual Ratios
H. Lundbeck AS, Annual Ratios (Cont...1)
H. Lundbeck AS, Annual Ratios (Cont...2)
H. Lundbeck AS, Interim Ratios
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
H. Lundbeck AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[H. Lundbeck AS (LUN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Enerkem Inc:企業の戦略的SWOT分析
    Enerkem Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Tokyu Corporation:企業の戦略・SWOT・財務情報
    Tokyu Corporation - Strategy, SWOT and Corporate Finance Report Summary Tokyu Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • ImaginAb Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary ImaginAb Inc (ImaginAb) is an immune and oncology imaging company that develops in vivo antibody-based imaging agents. It is engaged in the discovery, development, and production of new compounds and products in human health and cosmetics, agriculture and food sectors. The company’s product …
  • North Energy ASA (NORTH):石油・ガス:M&Aディール及び事業提携情報
    Summary North Energy ASA (North Energy) is an upstream oil and gas company that provides exploration and development services in Norwegian Continental Shelf (NCS). The company’s services include oil and gas exploration and development, license mapping and drilling programs, and conducting geological …
  • Black Knight Inc (BKI):企業の財務・戦略的SWOT分析
    Black Knight Inc (BKI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Flexion Therapeutics Inc (FLXN):企業の財務・戦略的SWOT分析
    Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Firestone Diamonds plc:企業の戦略・SWOT・財務情報
    Firestone Diamonds plc - Strategy, SWOT and Corporate Finance Report Summary Firestone Diamonds plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • MannKind Corp (MNKD):企業の財務・戦略的SWOT分析
    MannKind Corp (MNKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Foundation Medicine Inc (FMI):医療機器:M&Aディール及び事業提携情報
    Summary Foundation Medicine Inc (Foundation Medicine), a subsidiary of F. Hoffmann-La Roche Ltd, is a molecular information products provider. The company provides molecular information and cancer research programs. It offers clinical products such as FoundationOne for solid tumors and FoundationOne …
  • Breas Medical AB:医療機器:M&Aディール及び事業提携情報
    Summary Breas Medical AB (Breas), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, is a medical device company that manufactures and markets medical devices for anesthesia and respiratory markets. The company provides isleep and vivo products. It provides products such as isleep, vivo 3 …
  • Hydro-Quebec-エネルギー分野:企業M&A・提携分析
    Summary Hydro-Quebec is a government-owned energy utility that generates, transmits and distributes electricity. The company specializes in renewable energy generation, using hydro sources and supports the development of electricity using other technologies such as wind energy and biomass. It genera …
  • Kane Biotech Inc (KNE):企業の財務・戦略的SWOT分析
    Summary Kane Biotech Inc (Kane Biotech) is a developer of pharmaceutical products that prevent and remove microbial biofilms. The company uses patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. It develop …
  • Rigel Pharmaceuticals Inc (RIGL):製薬・医療:M&Aディール及び事業提携情報
    Summary Rigel Pharmaceuticals Inc. (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease me …
  • Stada Arzneimittel AG (SAZ)-医療機器分野:企業M&A・提携分析
    Summary Stada Arzneimittel AG (STADA) is a pharmaceutical company that manufacturers low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It off …
  • Innovation Pharmaceuticals Inc (IPIX)-医療機器分野:企業M&A・提携分析
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company pipeline products include kevetrin for the …
  • Euler Hermes SA:戦略・SWOT・企業財務分析
    Euler Hermes SA - Strategy, SWOT and Corporate Finance Report Summary Euler Hermes SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Herman Miller Inc (MLHR):企業の財務・戦略的SWOT分析
    Herman Miller Inc (MLHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Grupo Carso SA de CV:企業の戦略・SWOT・財務分析
    Grupo Carso SA de CV - Strategy, SWOT and Corporate Finance Report Summary Grupo Carso SA de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bandai Namco Holdings Inc. (7832):企業の財務・戦略的SWOT分析
    Bandai Namco Holdings Inc. (7832) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Sagent Pharmaceuticals, Inc.:企業のM&A・事業提携・投資動向
    Sagent Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sagent Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆